Differential action of a protein tyrosine kinase inhibitor, genistein, on the positive inotropic effect of endothelin-1 and norepinephrine in canine ventricular myocardium

British Journal of Pharmacology

Volumn 144, Issue 3, 2005, Pages 430-442

  Chu, Li ^a,b   Zhang, Jian Xin ^a,c   Norota, Ikuo ^a   Endoh, Masao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c Hebei Institute of Medical Science   (China)

Author keywords

Ca 2+ transient; Dog ventricular myocardium; Endothelin 1; Inotropic effect; Norepinephrine; Tyrosine kinase

Indexed keywords

BETA ADRENERGIC RECEPTOR; CALCIUM ION; CARBACHOL; DAIDZEIN; ENDOTHELIN 1; ESTER DERIVATIVE; GENISTEIN; NORADRENALIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; VANADIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOG; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE WALL; INOTROPISM; MALE; MOLECULAR INTERACTION; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; CALCIUM SIGNALING; CARDIOTONIC AGENTS; CELL SEPARATION; DOGS; ENDOTHELIN-1; ENZYME INHIBITORS; GENISTEIN; HEART; HEART VENTRICLES; INDOLES; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; NOREPINEPHRINE; PROTEIN-TYROSINE KINASES; RECEPTOR CROSS-TALK; RECEPTORS, ADRENERGIC, BETA;

EID: 14644444569     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706097     Document Type: Article

References (68)

1. 1-receptors with histamine in guinea-pig left atrium. Br. J. Pharmacol., 130, 907-915.
2. AKIYAMA, T., ISHIDA, J., NAKAGAWA, S., OGAWARA, H., WATANABE, S., ITOH, N., SHIBUYA, M. & FUKAMI, Y. (1987). Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 262, 5592-5595.
3. AUGER, K.R., SERUNIAN, L.A., SOLTOFF, S.R., LIBBY, P. & CANTLEY, L.C. (1989). PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell, 57, 167-175.
4. 2+ current in guinea-pig ventricular myocytes. J. Physiol., 537, 779-792.
5. 2+ current cooperatively in human atrial myocytes. Am. J. Physiol., 278, H670-H676.
6. CATALDI, M., TAGLIALATELA, M., GUERRIERO, S., AMOROSO, S., LOMBARDI, G., DI RENZO, G. & ANNUNZIATO, L. (1996). Protein-tyrosine kinases activate while protein-tyrosine phosphatases inhibit L-type calcium current channel activity in pituitary GH3 cells. J. Biol. Chem., 271, 9441-9446.
7. CHIANG, C.E., CHEN, S.A., CHANG, M.S., LIN, C.I. & LUK, H.N. (1996). Genistein directly inhibits L-type calcium currents but potentiates cAMP-dependent chloride current in cardiomyocytes. Biochem. Biophys. Res. Commun., 223, 598-603.
8. CHU, L. & ENDOH, M. (2000). Biphasic inotropic response to endothelin-1 in the presence of various concentrations of norepinephrine in dog ventricular myocardium. J. Cardiovasc. Pharmacol., 36 (Suppl. 2), S9-S14.
9. CHU, L. & ENDOH, M. (2001). Genistein enhances the positive inotropic effect of norepinephrine, but inhibits the positive and negative inotropic effect of endothelin-1 induced by cross talk with norepinephrine in canine ventricular myocardium. Circulation, 89 (Suppl. 2), S21 (abstract).
10. CHU, L., NOROTA, I., ISHII, K. & ENDOH, M. (2003a). Inhibitory action of the phosphatase inhibitor cantharidin on the endothelin-1-induced and the carbachol-induced negative inotropic effect in the canine ventricular myocardium. J. Cardiovasc. Pharmacol., 41 (Suppl. 1), S89-S92.
11. 2+ signaling in contractile regulation induced by crosstalk between endothelin-1 and norepinephrine in dog ventricular myocardium. Circ. Res., 92, 1024-1032.
12. DI SALVO, J., STEUSLOFF, A., SEMENCHUK, L., SATOH, S., KOLQUIST, K. & PFITZER, G. (1993). Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle. Biochem. Biophys. Res. Commun., 190, 968-974.
13. 2+ signaling in mammalian atrial and ventricular myocardium. Eur. J. Pharmacol., 375, 177-196.
14. FANTL, W.J., JOHNSON, D.E. & WILLIAMS, L.T. (1993). Signalling by receptor tyrosine kinase. Annu. Rev. Biochem., 62, 453-481.
15. FLEICHMAN, M., SCHNEIDER, T., FETSCHER, C. & MICHEL, MC. (2004). Signal transduction underlying carbachol-induced contraction of rat urinary bladder. II. Protein kinases. J. Pharmacol. Exp. Ther., 308, 54-58.
16. GAZIT, A., YAISH, P., GILON, C. & LEVITZKI, A. (1989). Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem., 32, 2344-2352.
17. GORDON, J.A. (1991). Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol., 201, 477-482.
18. GOUTSOULIAK, V. & RABKIN, S.W. (1997). Angiotensin II-induced inositol phosphate generation is mediated through tyrosine kinase pathway in cardiomyocytes. Cell Signal., 9, 505-512.
19. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem., 260, 3440-3450.
20. 2-adrenergic receptors in response to insulin. J. Biol. Chem., 267, 26017-26022.
21. HAN, D.H., DENISON, M.S., TACHIBANA, H. & YAMADA, K. (2002). Relationship between estrogen receptor-binding and estrogenic activities of environmental estrogens and suppression by flavonoids. Biosci. Biotechnol. Biochem., 66, 1479-1487.
22. HO, A.K., WIEST, R., OGIWARA, T., MURDOCH, G. & CHIK, C.L. (1995). Potentiation of agonist-stimulated cyclic AMP accumulation by tyrosine kinase inhibitors in rat pinealocytes. J. Neurochem., 65, 1597-1603.
23. HOLLENBERG, M.D. (1994). Tyrosine kinase pathways and the regulation of smooth muscle contractility. Trends Pharmacol. Sci., 15, 108-114.
24. HOMMA, Y., SAKAMOTO, H., TSUNODA, M., AOKI, M., TAKENAWA, T. & OOYAMA, T. (1993). Evidence for involvement of phospholipase C-γ 2 in signal transduction of platelet-derived growth factor in vascular smooth muscle cells. Biochem. J., 290, 649-653.
25. HOOL, L.C., MIDDLETON, L.M. & HARVEY, R.D. (1998). Genistein increases the sensitivity of cardiac ion channels to β-adrenergic receptor stimulation. Circ. Res., 83, 33-42.
26. 2+ channels in rabbit colonic smooth muscle cells by c-Src and focal adhesion kinase. J. Biol. Chem., 273, 5337-5342.
27. 1 muscarinic acetylcholine receptor. Cell, 75, 1145-1156.
28. HUNTER, T. & COOPER, J.A. (1985). Protein-tyrosine kinases. Annu. Rev. Biochem., 54, 897-930.
29. 2-Adrenoceptor- mediated vasoconstriction requires a tyrosine kinase. Eur. J. Pharmacol., 277, 29-34.
30. KAROOR, V., BALTENSPERGER, K., PAUL, H., CZECH, M.P. & MALBON, C.C. (1995). Phosphorylation of tyrosyl residues 350/354 of the β-adrenergic receptor is obligatory for counterregulatory effects of insulin. J. Biol. Chem., 270, 25305-25308.
31. KUSAKA, M. & SPERELAKIS, N. (1995). Inhibition of L-type calcium current by genistein, a tyrosine kinase inhibitor, in pregnant rat myometrial cells. Biochim. Biophys. Acta, 1240, 196-200.
32. LIEW, R., MACLEOD, K.T. & COLLINS, P. (2003). Novel stimulatory actions of the phytoestrogen genistein: effects on the gain of cardiac excitation-contraction coupling. FASEB J., 17, 1307-1309.
33. MAHER, P.A. (1991). Tissue-dependent regulation of protein tyrosine kinase activity during embryonic development. J. Cell Biol., 112, 955-963.
34. MOLLOY, C.J., TAYLOR, D.S. & WEBER, H. (1993). Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aotric smooth muscle cells. J. Biol. Chem., 268, 7338-7345.
35. MURATA, M., MIDORIKAWA, K., KOH, M., UMEZAWA, K. & KAWANISHI, S. (2004). Genistein and daizein induce cell proliferation and their metabolites cause oxidative DNA damage in relation to isoflavone-induced cancer of estrogen-sensitive organs. Biochemistry, 43, 2569-2577.
36. OHANIAN, J., OHANIAN, V., SHAW, L., BRUCE, C. & HEAGERTY, A.M. (1997). Involvement of tyrosine phosphorylation in endothelin-induced calcium-sensitization in rat small mesenteric arteries. Br. J. Pharmacol., 120, 653-661.
37. PETERSON, G. & BARNES, S. (1993). Genistein and biochanin A inhibit the growth of human prostate cancer cell but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate, 22, 335-345.
38. REID, J.J., LIEU, A.T. & RAND, M.J. (1991). Interactions between endothelin-1 and other chronotropic agents in rat isolated atria. Eur. J. Pharmacol., 194, 173-181.
39. SADOSHIMA, J., XU, Y., SLAYTER, H.S. & IZUMO, S. (1993). Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell, 75, 977-984.
40. SAKAI, S., MIYAUCHI, T., KOBAYASHI, M., YAMAGUCHI, I., GOTO, K. & SUGISHITA, Y. (1996). Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature, 384, 353-355.
41. 2-adrenoceptor activation in rat aortic rings. J. Cardiovasc. Pharmacol., 35, 227-233.
42. SATAKE, N., IMANISHI, M. & SHIBATA, S. (1999). Increased nitroglycerin-induced relaxation by genistein in rat aortic rings. Eur. J. Pharmacol., 377, 193-197.
43. SATAKE, N. & SHIBATA, S. (1999). The potentiating effect of genistein on the relaxation induced by isoproterenol in rat aortic rings. Gen. Pharmacol., 33, 221-227.
44. SCHOLAR, E.M. & TOEWS, M.L. (1994). Inhibition of invasion of murine mammary carcinoma cells by the tyrosine kinase inhibitor genistein. Cancer Lett., 87, 159-162.
45. SIEGELBAUM, S.A. (1994). Ion channel control by tyrosine phosphorylation. Curr. Biol., 4, 242-245.
46. SHUBA, L.M., ASAI, T., PELZER, S. & MCDONALD, T.F. (1996). Activation of cardiac chloride conductance by the tyrosine kinase inhibitor, genistein. Br. J. Pharmacol., 119, 335-345.
47. SIMS, C., CHIU, J. & HARVEY, R.D. (2000). Tyrosine phosphatase inhibitors selectively antagonize beta-adrenergic receptor-dependent regulation of cardiac ion channels. Mol. Pharmacol., 58, 1213-1221.
48. TAKANASHI, M. & ENDOH, M. (1991). Characterization of the positive inotropic effect of endothelin on mammalian ventricular myocardium. Am. J. Physiol., 261, H611-H619.
49. 2+ signaling in aequorin-loaded canine right ventricular myocardium. Jpn. J. Pharmacol., 85 (Suppl.), S81 (abstract).
50. TALUKDER, M.A., NOROTA, I., SAKURAI, K. & ENDOH, M. (2001). Inotropic response of rabbit ventricular myocytes to endothelin-1: difference from isolated papillary muscles. Am. J. Physiol., 281, H596-H605.
51. TASKINEN, P., TOTH, M. & RUSKOAHO, H. (1994). Effects of genistein on cardiac contractile force and atrial natriuretic peptide secretion in the isolated perfused rat heart. Eur. J. Pharmacol., 256, 251-261.
52. THORBURN, J. & THORBURN, A. (1994). The tyrosine kinase inhibitor, genistein, prevents α-adrenergic-induced cardiac muscle cell hypertrophy by inhibiting activation of the Ras-MAP kinase signaling pathway. Biochem. Biophys. Res. Commun., 202, 1586-1591.
53. TSIANI, E. & FANTUS, I.G. (1997). Vanadium compounds. Biological actions and potential as pharmacological agents. Trends Endocrinol. Metab., 8, 51-58.
54. TSUDA, T., KAWAHARA, Y., SHII, K., KOIDE, M., ISHIDA, Y. & YOKOYAMA, M. (1991). Vasoconstrictor-induced protein-tyrosine phosphorylation in cultured vascular smooth muscle cells. FEBS Lett., 285, 44-48.
55. VAN DER GEER, P., HUNTER, T. & LINDBERG, R.A. (1994). Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol., 10, 251-337.
56. WALKER, C.A., ERGUL, A., GRUBBS, A., ZILE, M.R., ZELLNER, J.L., CRUMBLEY, A.J. & SPINALE, F.G. (2001). β-Adrenergic and endothelin receptor interaction in dilated human cardiomyopathetic myocardium. J. Cardiac Fail., 7, 129-137.
57. 2+ sensitivity in rabbit ventricular myocytes. Eur. J. Pharmacol., 424, 91-96.
58. 2+ current in feline atrial myocytes. Am. J. Physiol., 275, H204-H212.
59. 2+ current in rabbit ventricular myocytes. Naunyn-Schmiedeberg's Arch. Pharmacol., 360, 654-664.
60. 2+ current in dog ventricular myocytes. J. Cardiovasc. Pharmacol., 36, 344-350.
61. WEI, C.M., LERMAN, A., RODEHEFFER, R.J., MCGREGOR, C.G., BRANDT, R.R., WRIGHT, S., HEUBLEIN, D.M., KAO, P.C., EDWARDS, W.D. & BURNETT, J.C. (1994). Endothelin in human congestive heart failure. Circulation, 89, 1580-1586.
62. WIJETUNGE, S., AALKJAER, C., SCHACHTER, M. & HUGHES, A.D. (1992). Tyrosine kinase inhibitors block calcium channel currents in vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 189, 1620-1623.
63. YANAGISAWA, M., KUSUMOTO, H., KIMURA, S., TOMOBE, Y., KOBAYASHI, M., MITSUI, Y., YAZAKI, Y., GOTO, K. & MASAKI, T. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332, 411-415.
64. YANG, S.G., SAIFEDDINE, M. & HOLLENBERG, M.D. (1992). Tyrosine kinase inhibitors and the contractile action of epidermal growth factor-urogastrone and other agonists in gastric smooth muscle. Can. J. Physiol Pharmacol., 70, 85-93.
65. YANG, S.G., SAIFEDDINE, M., LANIYONU, A. & HOLLENBERG, M.D. (1993). Distinct signal transduction pathways for angiotensin-II in guinea pig gastric smooth muscle: differential blockade by indomethacin and tyrosine kinase inhibitors. J. Pharmacol. Exp. Ther., 264, 958-966.
66. YOKOSHIKI, H., SUMII, K. & SPERELAKIS, N. (1996). Inhibition of L-type calcium current in rat ventricular cells by the tyrosine kinase inhibitor, genistein and its inactive analog, daidzein. J. Mol. Cell Cardiol., 28, 807-814.
67. YOMOGIDA, S., MARUYA, J., NOROTA, I., ISHII, K. & ENDOH, M. (2004). Differential inhibition by TAK-044 of the inotropic effects of endothelin-1 and endothelin-3. Eur. J. Pharmacol., 492, 217-224.
68. ZHU, Y., YANG, T.H. & ENDOH, M. (1997). Negative chronotropic and inotropic effects of endothelin isopeptides in mammalian cardiac muscle. Am. J. Physiol., 273, H119-H127.